SAF-NRVSNCT07116811
Steroids for Facial Nerve Function Protection in Post-surgical Vestibular Schwannoma Patients
At risk: Primary completion moved 1 year 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 30, 2026 to Dec 30, 2027 Show 7 more changesShow less
- Recruitment opened
- Eligibility criteria expanded, about 12 words
- Study completion pushed from Sep 30, 2027 to Mar 30, 2028
- Start date changed from estimate of Sep 1, 2025 to Oct 9, 2025
- Secondary endpoints: details revised at 2 of 9 entries
- Study description revised
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Good facial nerve function (House-Brackmann grade I or II) at 90 days after surgery
Timeframe: at 90 (±7) days after surgery
Secondary (9)
Good facial nerve function (House-Brackmann grade I or II) at 10 days after surgery
Complete facial nerve function recovery (House-Brackmann grade I) at 90 days after surgery
Complete facial nerve function recovery (House-Brackmann grade I) at 10 days after surgery
Complete facial nerve function recovery (Sunnybrook scale 100 score) at 90 days after surgery
Complete facial nerve function recovery (Sunnybrook scale 100 score) at 10 days after surgery
Show 4 moreShow less
Adverse events within 90 days
Serious adverse events within 90 days
Adverse events within 10 days
Serious adverse events within 10 days
Arms and interventions
Steroids GroupExperimental
Methylprednisolone sodium succinate (80 mg/day) on days 1-3 post-surgery, followed by prednisone acetate (20 mg/day) on days 4-10.
Placebo GroupPlacebo comparator
Methylprednisolone sodium succinate placebo on days 1-3 post-surgery, followed by prednisone acetate placebo on days 4-10.
Drugs: Steroids therapy, Placebo
Sites
1 site in 1 country
- Beijing Tiantan HospitalBeijing, Beijing Municipality, China